BIOMAT Database Logo BIOMAT Database Logo

The role of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. 2023

Jorge Avila, and José Pablo Leone
Department of Internal Medicine, St. Elizabeth's Medical Center, Boston, MA, USA.

UI MeSH Term Description Entries

Related Publications

Jorge Avila, and José Pablo Leone
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
October 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Jorge Avila, and José Pablo Leone
Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
January 2023, Frontiers in oncology,
Jorge Avila, and José Pablo Leone
Sacituzumab Govitecan in Hormone Receptor-Positive Metastatic Breast Cancer.
March 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Jorge Avila, and José Pablo Leone
[Sacituzumab-govitecan in hormone-receptor positive/HER2-negative advanced breast cancer].
April 2024, Bulletin du cancer,
Jorge Avila, and José Pablo Leone
Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer.
November 2021, Breast cancer research and treatment,
Jorge Avila, and José Pablo Leone
Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer.
March 2023, Annals of translational medicine,
Jorge Avila, and José Pablo Leone
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
October 2023, Lancet (London, England),
Jorge Avila, and José Pablo Leone
Sacituzumab govitecan for hormone receptor-positive and triple-negative breast cancers.
January 2023, Molecular and cellular pharmacology,
Jorge Avila, and José Pablo Leone
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
April 2021, The New England journal of medicine,
Jorge Avila, and José Pablo Leone
Sacituzumab govitecan (Trodelvy) for metastatic triple-negative breast cancer.
February 2021, The Medical letter on drugs and therapeutics,
Copied contents to your clipboard!